Table 1.

Characteristics of TMD subjects

SubjectAge (years)GenderDuration of pain (years)SitePain intensity week before scanning (10 cm VAS)Pain intensity before scan (10 cm VAS)Analgesic medication
15138F6Right1.84.7Paracetamol
20159M20Bilateral5.96.0Amitriptyline hydrochloride
20359F30Bilateral7.97.6Venlafaxine, co-codamol
20653F3Bilateral2.53.1None
22847M20Bilateral2.92.7Paracetamol (PRN)
25342F3Bilateral0.20None
25670F11Bilateral0.74.6Aspirin
25962F5Bilateral5.43.9Diazepam, paracetamol
26745F2Bilateral1.51.1None
26837M6Bilateral7.37.0Botox
27541F4Right1.40.5None
29050F46Bilateral4.36.5Diclofenac
29445F5.5Bilateral4.17.3Oxycodone (PRN), paracetamol, co-codamol (PRN), doxylamine succinate, and codeine
29533F15Right5.95.5Doxylamine succinate and codeine (PRN)
30028M1.5Bilateral5.86.7Ibuprofen (PRN)
30124F7Bilateral5.55.9Amitriptyline hydrochloride, co-codamol, and sumatriptan
30466F5Bilateral3.11.1None
31350F3Bilateral2.72.0None
31437F4Bilateral2.25.5Ibuprofen (PRN)
31730F2Bilateral3.51.7Ibuprofen and paracetamol
Mean ± SEM46 ± 2.911.5 ± 3.43.7 ± 0.54.2 ± 0.5
  • All TMD patients fulfilled the criteria for TMD according to the Research Diagnostic Criteria for TMD (Dworkin and LeResche, 1992). PRN, Pro re nata (“as needed”); F, female; M, male.